SELLAS Life Sciences Group (NASDAQ:SLS) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Key Points

• SELLAS reported a quarterly loss of $0.05 per share, missing analysts’ consensus estimate of a $0.04 loss by $0.01.
• SLS shares rose 0.1% to $11.05, although the stock remains volatile, with a 52-week range of $1.39 to $15.88 and a market capitalization of approximately $2.17 billion.
• Analyst sentiment is mixed, with two Buy ratings and one Sell rating producing an overall “Hold” consensus and a $10.00 average price target. Institutional investors own 17.38% of the company.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01), FiscalAI reports.

SELLAS Life Sciences Group Stock Up 0.1%

SLS traded up $0.01 during trading on Tuesday, reaching $11.05. The company had a trading volume of 4,565,608 shares, compared to its average volume of 8,285,710. The stock has a market cap of $2.17 billion, a P/E ratio of -48.04 and a beta of 2.48. The business has a 50 day simple moving average of $10.95 and a 200-day simple moving average of $7.19. SELLAS Life Sciences Group has a 52 week low of $1.39 and a 52 week high of $15.88.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on SLS shares. Alliance Global Partners reissued a "buy" rating on shares of SELLAS Life Sciences Group in a research note on Monday, July 6th. Weiss Ratings restated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, SELLAS Life Sciences Group presently has an average rating of "Hold" and a consensus target price of $10.00.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of SELLAS Life Sciences Group by 2.8% during the 3rd quarter. Vanguard Group Inc. now owns 6,839,905 shares of the company's stock worth $11,012,000 after purchasing an additional 185,106 shares during the period. Geode Capital Management LLC raised its position in SELLAS Life Sciences Group by 35.9% in the 4th quarter. Geode Capital Management LLC now owns 3,077,337 shares of the company's stock worth $11,604,000 after purchasing an additional 812,953 shares during the period. Marshall Wace LLP lifted its stake in SELLAS Life Sciences Group by 23,550.0% in the second quarter. Marshall Wace LLP now owns 2,715,489 shares of the company's stock worth $5,947,000 after purchasing an additional 2,704,007 shares during the last quarter. State Street Corp lifted its stake in SELLAS Life Sciences Group by 60.8% in the fourth quarter. State Street Corp now owns 2,188,171 shares of the company's stock worth $8,249,000 after purchasing an additional 827,257 shares during the last quarter. Finally, Millennium Management LLC boosted its position in shares of SELLAS Life Sciences Group by 341.0% during the fourth quarter. Millennium Management LLC now owns 1,387,849 shares of the company's stock valued at $5,232,000 after buying an additional 1,073,147 shares during the period. Hedge funds and other institutional investors own 17.38% of the company's stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source